Novartis breaks ground in Russia; Lupin eyes bigger margins long term;

@FiercePharma: Forest fights back against Icahn in filing. Article | Follow @FiercePharma

> Novartis has started construction of its new St. Petersburg manufacturing plant, the centrepiece of its planned, $500 million five-year investment into Russia. Article

> Lupin may find it tough to improve its operating margin this fiscal year, but the Indian generics maker's profitability is expected to jump in a couple of years, helped mainly by the launch of several lucrative products in the U.S. Item

> European regulators have followed FDA in granting marketing authorization for Bristol-Myers Squibb's Nulojix, which aims to prevent kidney transplant patients rejecting their new organ. Report

> Eli Lilly and Amylin Pharmaceuticals may put their disagreements over marketing pacts to one side temporarily after European regulators gave the thumbs-up to their once-weekly diabetes drug Bydureon. Story

> A recent meeting with Pfizer managers has confirmed optimism that the drugmaker will not be abandoning Groton, CT, completely, chamber officials said. News

> Sun Pharma won the FDA nod for its generic version of GlaxoSmithKline's migraine drug Imitrex. Item

Biotech News

@FierceBiotech: Abbott inks $470M pact for Biotest's Ph2 RA antibody program. Story | Follow @FierceBiotech

@JohnCFierce: This Tesaro deal reminds me of the success Clovis has had in raising big $$$. Experience+clear strategy in cancer is appealing to investors. | Follow @JohnCFierce

> FDA's safety concerns force Merck KGaA to kill cladribine MS program. Report

> FDA experts reject Novartis gout drug. Story

Drug Delivery News

> FDA looking for advice on regulating nanotech. Story

> Europe's Bydureon approval is victory for Alkermes. Report

> J&J drops Cypher drug-coated stents in more bad news for SurModics. Piece

> Body's blood-clotting machinery harnessed against cancer. Item

> Neural probe to include microchannels to deliver drugs to tinnitus sufferers. Article

> NIST to test the value of gold in drug-delivering nanoparticles. Article

Medical Device News

> Medtronic faces Senate scrutiny over Infuse. Article

> 3M accuses Porton CEO of blackmail. News

> GAO: FDA doesn't oversee device recalls properly. Article

> AZ, Dentsply reach deal on Astra Tech. Story

> Mauna Kea looks to raise $67.7M in IPO. Report

> Mendor raises $11.7M in Series B. Item

And Finally... To build up its medical device business in rural parts of India and China, Johnson & Johnson is focusing heavily on a strategy that involves simplifying things. Report